BR0015172A - Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno - Google Patents

Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Info

Publication number
BR0015172A
BR0015172A BR0015172-6A BR0015172A BR0015172A BR 0015172 A BR0015172 A BR 0015172A BR 0015172 A BR0015172 A BR 0015172A BR 0015172 A BR0015172 A BR 0015172A
Authority
BR
Brazil
Prior art keywords
beta
receptor antagonist
new combination
agonist
leukotriene receptor
Prior art date
Application number
BR0015172-6A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0015172A publication Critical patent/BR0015172A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"NOVA COMBINAçãO COMPREENDENDO UM AGONISTA ADRENO RECEPTOR DE BETA 2 (<225>~ 2~) E UM ANTAGONISTA RECEPTOR DE LEUCOTRIENO". A presente invenção proporciona uma composição farmacêutica, um produto farmacêutico ou um kit farmacêutico compreendendo um primeiro ingrediente ativo que é um agonista adreno receptor de beta 2 (<225>~ 2~) selecionado a partir de formoterol e derivados farmaceuticamente aceitáveis do mesmo, e um segundo ingrediente ativo que é um antagonista receptor de leucotrieno selecionado a partir de zafirlukast, montelukast e seus derivados farmaceuticamente aceitáveis, para utilização no tratamento de disfunções inflamatórias.
BR0015172-6A 1999-11-03 2000-10-27 Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno BR0015172A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination
PCT/SE2000/002115 WO2001032163A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST

Publications (1)

Publication Number Publication Date
BR0015172A true BR0015172A (pt) 2002-06-18

Family

ID=20417605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015172-6A BR0015172A (pt) 1999-11-03 2000-10-27 Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Country Status (13)

Country Link
EP (1) EP1242065A1 (pt)
JP (1) JP2003513037A (pt)
KR (1) KR20020050254A (pt)
CN (1) CN1387431A (pt)
AU (2) AU1321401A (pt)
BR (1) BR0015172A (pt)
CA (1) CA2388657A1 (pt)
IL (1) IL149365A0 (pt)
MX (1) MXPA02004334A (pt)
NO (1) NO20022103L (pt)
SE (1) SE9903995D0 (pt)
WO (2) WO2001032163A1 (pt)
ZA (1) ZA200203178B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1742625A1 (en) * 2004-04-05 2007-01-17 Sepracor, Inc. (r,r)-formoterol in combination with other pharmacological agents
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
SI1863476T1 (sl) * 2005-03-16 2016-05-31 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
WO2012168226A1 (en) * 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN104822659A (zh) * 2012-12-05 2015-08-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇衍生物
JP5846185B2 (ja) 2013-11-21 2016-01-20 大日本印刷株式会社 貫通電極基板及び貫通電極基板を用いた半導体装置
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604752D0 (sv) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
ATE317224T1 (de) * 1997-03-13 2006-02-15 Merck & Co Inc Chinolin-leukotrien-antagonisten
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use

Also Published As

Publication number Publication date
NO20022103D0 (no) 2002-05-02
NO20022103L (no) 2002-05-02
CA2388657A1 (en) 2001-05-10
IL149365A0 (en) 2002-11-10
AU1321401A (en) 2001-05-14
CN1387431A (zh) 2002-12-25
MXPA02004334A (es) 2002-11-07
WO2001032163A1 (en) 2001-05-10
AU1652601A (en) 2001-05-14
KR20020050254A (ko) 2002-06-26
EP1242065A1 (en) 2002-09-25
ZA200203178B (en) 2003-07-22
WO2001032166A1 (en) 2001-05-10
JP2003513037A (ja) 2003-04-08
SE9903995D0 (sv) 1999-11-03

Similar Documents

Publication Publication Date Title
BR9806801A (pt) Utilização de um antagonista de receptores cb1, composição farmacêutica, e, estojo para o tratamento de distúrbios da apetência
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
AU2001285451A1 (en) 2,4-substituted pyridine derivatives
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
BRPI0113669B8 (pt) n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]-amino]metil]fenil]-2e-2-propenamida, composição farmacêutica compreendendo o mesmo e uso
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
BR9812886A (pt) Uso de um atagonista de recptor de 5-ht3 ou de um seu derivado farmaceuticamente aceitável, processo para tratamento de ibs em fêmeas não-constipadas, e, antagonista de recpetor de 5-ht3 ou seu derivado farmaceuticamente aceitável
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
BR0016275A (pt) Combinações farmacêuticas e seu uso no tratamento de distúrbios gastrointestinais
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
BR0017338A (pt) Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR9915111A (pt) Partìculas revestidas de ibuprofeno cristalinogranulado
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
BR0317771A (pt) Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
BR9810337A (pt) Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]